CA2214431A1 - Human vegf-specific antisense oligonucleotides - Google Patents

Human vegf-specific antisense oligonucleotides

Info

Publication number
CA2214431A1
CA2214431A1 CA002214431A CA2214431A CA2214431A1 CA 2214431 A1 CA2214431 A1 CA 2214431A1 CA 002214431 A CA002214431 A CA 002214431A CA 2214431 A CA2214431 A CA 2214431A CA 2214431 A1 CA2214431 A1 CA 2214431A1
Authority
CA
Canada
Prior art keywords
antisense oligonucleotides
human vegf
specific antisense
vegf
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002214431A
Other languages
French (fr)
Other versions
CA2214431C (en
Inventor
Gregory S. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/398,945 external-priority patent/US5639872A/en
Priority claimed from US08/569,926 external-priority patent/US5641756A/en
Application filed by Individual filed Critical Individual
Publication of CA2214431A1 publication Critical patent/CA2214431A1/en
Application granted granted Critical
Publication of CA2214431C publication Critical patent/CA2214431C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Abstract

Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides and method useful for treating various disorders associated with neovascularization and angiogenesis.
CA002214431A 1995-03-02 1996-02-29 Human vegf-specific antisense oligonucleotides Expired - Fee Related CA2214431C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/398,945 1995-03-02
US08/398,945 US5639872A (en) 1993-07-27 1995-03-02 Human VEGF-specific oligonucleotides
US08/569,926 US5641756A (en) 1993-07-27 1995-12-08 Modified VEGF oligonucleotides
US08/569,926 1995-12-08
PCT/US1996/002840 WO1996027006A2 (en) 1995-03-02 1996-02-29 Human vegf-specific antisense oligonucleotides

Publications (2)

Publication Number Publication Date
CA2214431A1 true CA2214431A1 (en) 1996-09-06
CA2214431C CA2214431C (en) 2007-06-05

Family

ID=38137576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214431A Expired - Fee Related CA2214431C (en) 1995-03-02 1996-02-29 Human vegf-specific antisense oligonucleotides

Country Status (1)

Country Link
CA (1) CA2214431C (en)

Also Published As

Publication number Publication date
CA2214431C (en) 2007-06-05

Similar Documents

Publication Publication Date Title
AU5179196A (en) Human vegf-specific antisense oligonucleotides
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
HUP9701096A3 (en) Use of benzenesulfonamides for the preparation of pharmaceutical compositions treating disorders of the central nervous system, novel derivatives, process for their preparation and pharmaceutical compositions containing them
CA2223769A1 (en) Method of treatment for asthma
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
WO1996013512A3 (en) L-ribofuranosyl nucleosides
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
IL112664A (en) 4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
ZA9810122B (en) Treatment of T-helper cell type 2 mediated immune diseases
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
AU5229793A (en) Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics
HU9701416D0 (en) Phenyl-substituted guanidides of alkenyl-carboxylic acids, process for producing them, their use as medicine or diagnostics, and pharmaceutical compositions containing them
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
FR2689508B1 (en) IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.
AU1686997A (en) Modified vegf antisense oligonucleotides for treatment of skin disorders
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
CZ63895A3 (en) 5-vinyl-quinolone-carboxylic, 5-vinyl-naphthyridon-carboxylic, +5-ethinyl-quinolone-carboxylic and 5-ethinyl-naphthyridon-carboxylic acids, process of their preparation, medicaments in which said compounds are comprised and their use
GB9515356D0 (en) Improvements in or relating to delivery of nucleic acid
AU1867297A (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
CA2214431A1 (en) Human vegf-specific antisense oligonucleotides
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
GR3034886T3 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and their use in the production of pharmaceutical preparations as well as pharmaceutical preparations containing them
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140228